The practice-changing Keynote B15 trial showed strong efficacy for neoadjuvant EV-Pembro. However, about half of patients discontinued treatment due to side effects. This creates a clinical paradox: patients who complete the full regimen may be over-treated, while those who stop early due to toxicity may be under-treated, complicating patient management and counseling.
A Phase II trial of cabozantinib in heavily pre-treated, relapsed/refractory germ cell tumors demonstrated a clinical benefit rate of 43.2%. This marks a significant breakthrough as the first non-chemotherapy agent to show meaningful activity in this chemo-veteran population, offering a new therapeutic avenue for patients with limited options beyond aggressive chemotherapy and stem cell transplant.
A meta-analysis of six trials (Poseidon) found no overall survival benefit from adding long-course (24 months) hormone therapy to post-operative radiotherapy. It suggests that a shorter course of 4-6 months is adequate for most men, marking a significant shift towards treatment de-escalation to reduce long-term toxicity without compromising efficacy in this specific setting.
The BRCA-Way trial showed a combination of abiraterone and olaparib was effective. However, its relevance is limited as many patients now receive abiraterone upfront. The next-generation TALENT trial is designed specifically to address this, testing if re-challenging with an AR-pathway inhibitor alongside a PARP inhibitor is beneficial, demonstrating how trial design must constantly evolve to answer questions raised by new standards of care.